Dissolution of uric acid stones in the ureter

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Introduction. Uric acid stones (UA), consisting of uric acid/uric acid dihydrate, occur in 6.1-15.1% of all cases of urolithiasis in industrialized countries. At the same time, the frequency of these stones is directly dependent on age. Thus, the incidence of UA reaches 40% in men over 80 years of age and 27.3% in women over 90 years of age. UA are the only stones that are amenable to dissolution therapy with the use of citrate salts that alkalinize urine pH. A number of authors and European Association of Urology guidelines consider stone dissolution as a first-line therapy in the treatment of patients with UA, both as monotherapy and in combination with surgical procedures. Materials and methods. The results of conservative treatment of 86 patients aged 28 to 78 years with radiolucent ureteral stones ranging in size from 3 to 25 mm and a density of 133 to 728 HU, who underwent 89 courses of stone dissolution therapy from 2011 to 2018, are presented in the article. They had no obstruction or were prestented. There were 52 men (n=55 courses) and 34 women (n=34 courses). Results. In 78 out of 89 clinical cases (87.6%), stone-free status was obtained within 14 to 181 days. Most often the duration of therapy was 30 days. In 11 (12.4%) cases the treatment was considered ineffective. However, only in 4 (4.5%) patients the stone size did not change, while in 7 (7.9%) cases it decreased. The results of the study suggest the high efficiency of citrate therapy in patients with ureteral stones in case of unobstructed urine outflow (including those with stents), which is comparable to surgical treatment.

Full Text

Restricted Access

About the authors

E. A Frolova

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: frolo-ekaterin@yandex.ru
Ph.D., urologist of the UKB №2 Moscow, Russia

D. G Tsarichenko

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: tsarichenkodg@yandex.ru
Institute of Urology and Reproductive Health; h.D., MD, professor Moscow, Russia

V. S Saenko

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: saenko_vs@mail.ru
Institute of Urology and Reproductive Health; MD, professor Moscow, Russia

L. M Rapoport

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: leonidrapoport@yandex.ru
Institute of Urology and Reproductive Health; Ph.D., MD, professor, Deputy Director on Medical care Moscow, Russia

P. V Glybochko

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: rektorat@sechenov.ru
Institute of Urology and Reproductive Health; Ph.D., MD, academician of RSA, Rector, Director Moscow, Russia


  1. Sorokin I., Mamoulakis C., Miyazawa K. et al. Epidemiology of stone disease across the world. World Journal of Urology. 2017:1-20.
  2. Борисов В.В., Дзеранов Н.К. Мочекаменная болезнь. Терапия больных камнями почек и мочеточников. М., 2011. 88 с.
  3. Кузьмина Ф.М. Метафилактика мочекаменной болезни на основе прогнозирования риска рецидива заболевания: Кузьмина Фарида Мансуровна Саратов, 2010.
  4. Ненашева Н.П., Поповкин Н.Н., Орлова Е.В. и соавт. Динамика урологической заболеваемости по регионам Российской Федерации. Пленум правления Российского общества урологов: Материалы, Саратов, 1998:215-216.
  5. Голованов С., Сивков А., Дзеранов Н. и соавт. Распространенность метаболических типов мочекаменной болезни в Московском регионе: сравнительный анализ за период с 1990 по 2000 г. Экспериментальная и клиническая урология; 2010;3:27-32.
  6. Lieske J.C., Rule A.D., Krambeck A.E., et al. Stone composition as a function of age and sex. Clinical Journal of the American Society of Nephrology. 2014;9(12):2141-2146.
  7. Knoll T., Schubert A.B., Fahlenkamp D. et al. Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. The Journal of urology. 2011;185(4):1304-1311.
  8. Daudon M, Dore J-C, Jungers P et al. Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urological research. 2004;32(3):241-247.
  9. Daudon M., Lacour B., Jungers P. High prevalence of uric acid calculi in di abetic stone formers. Nephrology Dialysis Transplantation. 2005; 20(2):468-469.
  10. Marchini G.S., Sarkissian C., Tian D. et al. Stone composition and urinary stone risk: a matched case comparative study. The Journal of urology. 2013;189(4):1334-1339.
  11. Pak C., Sakhaee K., Moe O. et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003;61(3):523.
  12. Пытель Ю.А., Золотарев И.И. Уратный нефролитиаз. М: Медицина. 1995, 145 c.
  13. Wiederkehr M.R., Moe O.W. Uric acid nephrolithiasis: A systemic metabolic disorder. Clinical reviews in bone and mineral metabolism. 2011; 9(3-4):207-217.
  14. Abou-Elela A. Epidemiology, Pathophysiology And Management Of Uric Acid Urolithiasis: A Narrative Review. Journal of Advanced Research. 2017.
  15. Skolarikos A., Jung H.U. et al. EAU guidelines on urolithiasis 2022. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. Available at: uroweborg/guidelines/urolithiasis/.
  16. Калинина С.Н., Кореньков Д.Г., Мелконян А.Б. Опыт применения цитратной смеси Блемарен у больных с камнями мочеточников. Клиническая нефрология. 2013(5):30-32.
  17. Rodman J.S., Williams J.J., Peterson C.M. Dissolution of uric acid calculi. The Journal of urology. 1984;131(6):1039-1044.
  18. Dion M., Ankawi G., Chew B. et al. CUA guideline on the evaluation and medical management of the kidney stone patient-2016 update. CUAJ. 2016;10(11-12):E348.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies